Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Oncology

How Is Relapsed Follicular Lymphoma Treated?

At a Glance

Relapsed follicular lymphoma is a common and expected part of the disease, but it is highly treatable. Doctors use many effective therapies to regain control, including the non-chemo R2 regimen, targeted pills like tazemetostat, bispecific antibodies, and CAR T-cell therapy.

In this answer

3 sections

01

Initial Steps: Evaluating the Relapse

02

Typical Second-Line Options

03

Third-Line Therapies and Beyond

If your follicular lymphoma has returned after your first treatment, it is important to know that this is a normal, expected part of the disease. Follicular lymphoma is considered a chronic condition characterized by a natural cycle of responding to treatment, enjoying a period of remission, and eventually experiencing a relapse [1][2]. While hearing that the cancer has come back can be discouraging, the “bench” of available therapies is incredibly deep. Medical advancements over the past decade mean that doctors have many different, highly effective options to regain control of the disease, even if it relapses multiple times [3][4].

Initial Steps: Evaluating the Relapse

Before starting a new treatment, your care team will evaluate how the lymphoma is behaving. They will look at several individual factors, including your age, overall health, and how long your remission lasted [5][4].

  • Understanding POD24: A highly important factor is the timing of the relapse. If the lymphoma returns within 24 months of your initial chemoimmunotherapy (a milestone known as POD24), it signals that the cancer may be acting more aggressively [6][7]. In these early-relapse cases, doctors may recommend a more intensive approach, such as different chemotherapy combinations or sometimes a stem cell transplant, to achieve a deeper remission [8].
  • New Scans and Biopsies: Your doctor will likely order new imaging scans and may request a fresh biopsy of an enlarged lymph node. A new biopsy is crucial because follicular lymphoma can sometimes change (transform) into a faster-growing lymphoma [9]. The new tissue sample can also be tested for specific genetic mutations that might open the door to targeted pill therapies [10].

Typical Second-Line Options

When active treatment is needed again, your doctor will usually choose a “second-line” therapy that works differently from your first one. Common choices include:

  • Chemoimmunotherapy: If you were previously treated with a specific chemotherapy, your doctor might switch you to a different regimen (for instance, switching from bendamustine to a CHOP regimen, or vice versa) to attack the cancer from a new angle [11].
  • The R2 Regimen (Non-Chemo): A very common non-chemotherapy option for your first relapse is the R2 regimen, which combines the targeted pill lenalidomide with the immunotherapy infusion rituximab [12][13]. This approach avoids traditional chemotherapy side effects while stimulating your own immune system to find and attack the lymphoma cells.

Third-Line Therapies and Beyond

If the lymphoma returns again after your second-line treatment, you enter what is called the third-line setting. This is where some of the most cutting-edge, revolutionary therapies are used.

Targeted Therapies (Pills)

Researchers have developed daily pills that block specific pathways cancer cells need to survive. One major example is tazemetostat, an EZH2 inhibitor that has proven highly effective and generally well-tolerated for people with relapsed follicular lymphoma [10]. It is especially effective if the new biopsy shows your tumor has a specific genetic mutation called EZH2 [14].

Bispecific Antibodies

For patients who have relapsed after two or more prior treatments, bispecific antibodies like mosunetuzumab and epcoritamab are highly effective, “off-the-shelf” immunotherapy options [15][16]. These intravenous or injectable drugs have two “arms”: one grabs onto a specific target on the lymphoma cell, and the other grabs onto a healthy T-cell (part of your immune system), pulling them together so your immune system can destroy the cancer [17]. They have shown impressive abilities to achieve durable remissions [18].

CAR T-Cell Therapy

CAR T-cell therapy (such as lisocabtagene maraleucel, axicabtagene ciloleucel, or tisagenlecleucel) is a highly advanced approach typically used if the disease has returned after multiple prior treatments [19][20]. This process involves collecting your own T-cells, reprogramming them in a lab to seek out and attack lymphoma cells, and then infusing them back into your body [21]. While this treatment can lead to very high response rates and deep, long-lasting remissions [22], it carries risks of severe side effects—like widespread inflammation (cytokine release syndrome) and neurological issues—which require specialized monitoring [23][24].

Because follicular lymphoma is so responsive to these various treatments, a relapse is not the end of your options, but rather a pivot to the next strategy in a long-term management plan.

Common questions in this guide

What does it mean if my follicular lymphoma relapses early (POD24)?
If your lymphoma returns within 24 months of your initial treatment, it is known as POD24. This early relapse suggests the cancer may be acting more aggressively and often requires a more intensive treatment approach to achieve a deeper remission.
Will I need a new biopsy if my follicular lymphoma comes back?
Yes, your doctor will usually order a new biopsy of an enlarged lymph node. This is crucial to check if the cancer has changed into a faster-growing lymphoma and to test for specific genetic mutations, like EZH2, which can be treated with targeted daily pills.
What is the R2 regimen for relapsed follicular lymphoma?
The R2 regimen is a common non-chemotherapy option often used for a first relapse. It combines a targeted pill called lenalidomide with an immunotherapy infusion called rituximab to stimulate your immune system to find and destroy lymphoma cells.
What are bispecific antibodies and how do they work?
Bispecific antibodies are off-the-shelf immunotherapy drugs used when the disease returns after multiple prior treatments. They work by grabbing onto both a lymphoma cell and a healthy immune T-cell, pulling them together so your immune system can destroy the cancer.
When is CAR T-cell therapy used for follicular lymphoma?
CAR T-cell therapy is a highly advanced approach used if the lymphoma returns after multiple previous treatments. It involves collecting your own immune T-cells, reprogramming them in a lab to hunt down lymphoma cells, and infusing them back into your body.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my relapse occur within the POD24 window, and how does that affect our treatment plan?
  2. 2.Will I need a fresh biopsy to check for the EZH2 mutation or to rule out changes in the lymphoma?
  3. 3.Am I a good candidate for a non-chemotherapy approach like the R2 regimen?
  4. 4.Based on my health and previous treatments, what side effects should I be most prepared for with the next therapy?
  5. 5.At what point in my treatment journey should we start considering options like bispecific antibodies or CAR T-cell therapy?
  6. 6.Are there any clinical trials for relapsed follicular lymphoma that I might be eligible for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Are routine PET scans needed for follicular lymphoma?Can Follicular Lymphoma Be Cured? | Treatment OutlookCan You Live With Follicular Lymphoma Without Treatment?Does Follicular Lymphoma Treatment Cause Secondary Cancers?How Do I Manage Follicular Lymphoma Scanxiety?Is Watch and Wait Safe for Follicular Lymphoma?What Are the Rare Subtypes of Follicular Lymphoma?What Are the Side Effects of Rituximab Maintenance?What Are the Signs Follicular Lymphoma Is Progressing?What Does POD24 Mean in Follicular Lymphoma? ExplainedWhat is Grade 3B Follicular Lymphoma?What Is Histologic Transformation in Follicular Lymphoma?What is First-Line Treatment for Follicular Lymphoma?What is the FLIPI Score for Follicular Lymphoma?What is the Life Expectancy for Follicular Lymphoma?What is the t(14;18) Translocation in Follicular Lymphoma?

References

References (24)
  1. 1

    Early Progression of Follicular Lymphoma: Biology and Treatment.

    Lipof JJ, Barr PM

    Hematology/oncology clinics of North America 2020; (34(4)):757-769 doi:10.1016/j.hoc.2020.02.009.

    PMID: 32586579
  2. 2

    Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse-a case report.

    Suresh Babu MC, Thottian AGF, Lokanatha D, et al.

    Journal of the Egyptian National Cancer Institute 2020; (32(1)):22 doi:10.1186/s43046-020-00035-3.

    PMID: 32410046
  3. 3

    Prospects in the management of patients with follicular lymphoma beyond first-line therapy.

    Qualls D, Salles G

    Haematologica 2022; (107(1)):19-34 doi:10.3324/haematol.2021.278717.

    PMID: 34985231
  4. 4

    Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review.

    Fowler NH, Chavez JC, Riedell PA

    Targeted oncology 2024; (19(4)):495-510 doi:10.1007/s11523-024-01070-z.

    PMID: 38896212
  5. 5

    Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?

    Casulo C, Sehn LH

    Blood 2025; (146(15)):1782-1791 doi:10.1182/blood.2024026018.

    PMID: 40811857
  6. 6

    Progression of disease within 24 months of initial therapy (POD24) detected incidentally in imaging does not necessarily indicate worse outcome.

    Bitansky G, Avigdor A, Vasilev E, et al.

    Leukemia & lymphoma 2020; (61(11)):2645-2651 doi:10.1080/10428194.2020.1786554.

    PMID: 32643497
  7. 7

    Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.

    Casulo C, Byrtek M, Dawson KL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(23)):2516-22 doi:10.1200/JCO.2014.59.7534.

    PMID: 26124482
  8. 8

    Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world.

    Manna M, Lee-Ying R, Davies G, et al.

    Leukemia & lymphoma 2019; (60(1)):133-141 doi:10.1080/10428194.2018.1473576.

    PMID: 29966465
  9. 9

    Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

    Sarkozy C, Trneny M, Xerri L, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016; (34(22)):2575-82 doi:10.1200/JCO.2015.65.7163.

    PMID: 27298402
  10. 10

    Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.

    Morschhauser F, Tilly H, Chaidos A, et al.

    The Lancet. Oncology 2020; (21(11)):1433-1442 doi:10.1016/S1470-2045(20)30441-1.

    PMID: 33035457
  11. 11

    Outcome of extra-nodal follicular lymphoma affected by choice of induction chemoimmunotherapy and maintenance rituximab - real-world retrospective study.

    Ng LCK, Ong SY, Huang X, et al.

    Leukemia & lymphoma 2025; (66(5)):906-912 doi:10.1080/10428194.2024.2446615.

    PMID: 39731562
  12. 12

    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).

    Leonard JP, Jung SH, Johnson J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(31)):3635-40 doi:10.1200/JCO.2014.59.9258.

    PMID: 26304886
  13. 13

    Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.

    Li RC, Tang W, Zhang HL, et al.

    Genome medicine 2025; (17(1)):131 doi:10.1186/s13073-025-01557-y.

    PMID: 41137062
  14. 14

    Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.

    Izutsu K, Ando K, Nishikori M, et al.

    Cancer science 2021; (112(9)):3627-3635 doi:10.1111/cas.15040.

    PMID: 34159682
  15. 15

    Bispecific antibodies in follicular lymphoma.

    Nizamuddin IA, Bartlett NL

    Haematologica 2025; (110(7)):1472-1482 doi:10.3324/haematol.2024.285245.

    PMID: 39479864
  16. 16

    Mosunetuzumab and the emerging role of T-cell-engaging therapy in follicular lymphoma.

    Matarasso S, Assouline S

    Future oncology (London, England) 2023; (19(31)):2083-2101 doi:10.2217/fon-2023-0274.

    PMID: 37882361
  17. 17

    NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.

    Zelenetz AD, Gordon LI, Abramson JS, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2023; (21(11)):1118-1131 doi:10.6004/jnccn.2023.0057.

    PMID: 37935098
  18. 18

    Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.

    Budde LE, Sehn LH, Matasar M, et al.

    The Lancet. Oncology 2022; (23(8)):1055-1065 doi:10.1016/S1470-2045(22)00335-7.

    PMID: 35803286
  19. 19

    Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.

    Morschhauser F, Dahiya S, Palomba ML, et al.

    Nature medicine 2024; (30(8)):2199-2207 doi:10.1038/s41591-024-02986-9.

    PMID: 38830991
  20. 20

    CAR-T Cell Therapy for Follicular Lymphomas.

    Testa U, D'Alò F, Pelosi E, et al.

    Mediterranean journal of hematology and infectious diseases 2024; (16(1)):e2024012 doi:10.4084/MJHID.2024.012.

    PMID: 38223488
  21. 21

    Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.

    Fowler NH, Dickinson M, Dreyling M, et al.

    Nature medicine 2022; (28(2)):325-332 doi:10.1038/s41591-021-01622-0.

    PMID: 34921238
  22. 22

    The discovery and development of tisagenlecleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma.

    Kungwankiattichai S, Maziarz RT

    Expert opinion on drug discovery 2025; (20(11)):1357-1368 doi:10.1080/17460441.2025.2567291.

    PMID: 41039722
  23. 23

    Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives.

    Caridà G, Martino EA, Bruzzese A, et al.

    European journal of haematology 2025; (114(5)):775-784 doi:10.1111/ejh.14401.

    PMID: 39971627
  24. 24

    Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.

    Gust J, Finney OC, Li D, et al.

    Annals of neurology 2019; (86(1)):42-54 doi:10.1002/ana.25502.

    PMID: 31074527

This page provides educational information about treatments for relapsed follicular lymphoma. Always consult your oncologist or hematologist to determine the safest and most effective treatment plan for your specific situation.

Get notified when new evidence is published on Follicular lymphoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.